β-Nicotinamidemononucleotide, gereduceerde vorm (dinatrium) (standaard)

β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT)[2].

108347-85-9

Endogenous Metabolite; Reference Standards

Metabolic Enzyme/Protease; Others

Cancer

O[C@H]1[C@@H](O)[C@H](N2C=C(CC=C2)C(N)=O)O[C@@H]1COP(O[Na])(O[Na])=O

C11H15N2Na2O8P

380.20

[1]Liu Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. J Proteome Res. 2021 May 7;20 (5) :2596-2606.|[2]Zapata-Pérez R, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021 Apr;35 (4) :e21456.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W615108BR/

Reference Standards